Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study

Table 2 Changes of SCr, eGFR, and Cystatin-C, incidence of CIN

Variables	CoQ10 + TMZ group (n = 75)	Control group (n = 75)	p value
SCr (μmol/L)
Baseline	118.18 ± 17.27	119.38 ± 14.81	0.647
48 h after exposure	129.86 ± 21.75*	139.52 ± 20.21*	0.005
72 h after exposure	118.97 ± 16.82	125.06 ± 15.11*	0.021
eGFR (mL/min/1.73 m²)
Baseline	51.28 ± 5.03	50.36 ± 4.15	0.223
48 h after exposure	46.30 ± 5.69*	43.14 ± 5.81*	0.001
72 h after exposure	50.70 ± 5.57	48.50 ± 5.24*	0.014
Cystatin-C (mg/L)
Baseline	1.51 ± 0.26	1.53 ± 0.20	0.503
48 h after exposure	1.95 ± 0.43*	2.13 ± 0.35*	0.006
72 h after exposure	1.55 ± 0.27	1.64 ± 0.21*	0.016
Incidence of CIN, n (%)	5 (6.67)	16 (21.3)	0.010

SCr serum creatinine, eGFR estimated glomerular filtration rate, CIN contrast-induced nephropathy
* p < 0.05 compared with baseline

ISSN: 2047-783X